Pediatric vaccines market to reach $56.06b by 2031 as platforms evolve

Combination vaccines and next-generation platforms are expanding product portfolios.

The paediatric vaccines market is projected to reach $56.06b by 2031 from an estimated $42.53b in 2026, according to Mordor Intelligence.

Forecast to register a compound annual growth rate (CAGR) of 5.68% during the fiver-year period, its expansion will be supported by government funding, increasing adoption of multivalent formulations, growing immunisation awareness, and the development of next-generation vaccine platforms.

Asia-Pacific is emerging as the fastest-growing region in the paediatric vaccines market, supported by large birth cohorts, expanding healthcare infrastructure, rising healthcare expenditure, and government efforts to improve childhood immunisation coverage.

Countries including China, Japan, India, South Korea, and Australia are investing in vaccination programmes and healthcare modernisation, creating opportunities for vaccine manufacturers.

Manufacturers globally are developing higher-valent and combination vaccines designed to reduce the number of injections required during childhood immunisation schedules.

Multivalent vaccines are gaining importance as healthcare systems seek to simplify paediatric immunisation schedules and reduce the number of injections required.

Mordor Intelligence said these products are expected to remain an important component of vaccination programmes across developed and emerging markets.

Advances in mRNA, recombinant, viral-vector, and virus-like particle platforms are also creating opportunities for new paediatric vaccines and broader disease protection.

These technologies are being investigated to improve vaccine development, antigen design, scalability, and disease protection. Manufacturers are also exploring advanced platforms that could address diseases where existing paediatric vaccines provide limited protection.

Government agencies and non-governmental organisations continue to support the market through vaccine research, procurement, and distribution programmes.

Public-sector immunisation programmes provide manufacturers with predictable demand, whilst helping improve access to vaccines amongst children in underserved populations.

International funding initiatives and procurement programmes are particularly important across low- and middle-income countries, where healthcare infrastructure and affordability remain key barriers to vaccination coverage.

Digital technologies are increasingly being incorporated into vaccine distribution and inventory management.

Supply-chain automation, electronic tracking, digital immunisation registries, and blockchain-based traceability solutions can improve visibility across the vaccine distribution process.

These technologies can help healthcare providers monitor inventory, reduce wastage, track vaccine administration, and identify children who have missed scheduled doses.

Continued digitalisation is therefore expected to contribute to improved efficiency and access across paediatric immunisation programmes.